| # | |||
| I. MODIFIED AGREEMENTS | |||
| Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) |
Change from original agreement | Terms/Details (Date) |
| JUNE 1 — 25 | |||
| Alder Bio-pharmaceuticals Inc.* | Schering-Plough Corp. | Expanded its collaboration to include potential applications to central nervous system disorders | Alder will receive an up-front payment, committed funding for work on the project and milestone payments tied to the advancement of a therapeutic candidate, as well as future product royalties (6/8) |
| BioSeek Inc.* | Merck KGaA | Three-year collaboration extending and expanding the 2008 compound profiling agreement | BioSeek will continue to use its BioMAP latform to evaluate Merck Serono small-molecule compounds and proteins across multiple therapeutic areas for preclinical development (6/10) |
| Halozyme Therapeutics Inc. (HALO) | F. Hoffmann-La Roche Ltd. (Switzerland) | Partnership under which Roche selected a fifth target to be used with Halozyme's Enhanze biologics drug delivery platform | Roche will pay $4.25M for exclusive global rights to apply its hyaluronidase enzyme, rHuPH20, to the target (6/9) |
| MorphoSys AG (Germany; BE:MOR) | Schering-Plough Corp. | Schering-Plough triggered its option to extend the current antibody collaboration for another year | The deal grants Schering-Plough continued access to MorphoSys's antibody library HuCAL GOLD at its research site in Palo Alto, Calif. (6/16) |
| Trubion Pharmaceuticals Inc. (TRBN) | Wyeth | Agreement under which Wyeth exercised an option to extend research for one year through Dec. 22, 2010 | Wyeth's obligations include research funding of about $3.3M in exchange for committed research services; the deal involves Trubion's TRU-015 and other therapeutics (6/23) |
| II. TERMINATED AGREEMENTS | |||
| MannKind Corp. (MNKD) | Pfizer Inc. | Companies did not complete the deal for MannKind to purchase Pfizer's German insulin manufacturing plant because Sanofi-Aventis Group exercised its right of first refusal and bought the facility | MannKind still paid $3M in cash to acquire bulk insulin and a related manufacturing license (6/22) |
| Neuromed Pharmaceuticals Inc.* | Merck & Co. Inc. | Ended an agreement focused on pain therapeutics, or N-type calcium channel blockers | Merck said none of the compounds met the profile necessary to advance them; the deal, started in 2006, was valued at up to $475M (6/11) |
| Synta Pharmaceuticals Corp. (SNTA) | GlaxoSmithKline plc (UK) | Ended agreement for the development and commercialization of elesclomol effective no later than Sept. 10 | Worldwide rights to elesclomol will revert to Synta, and the company may pay GSK a low single-digit royalty on any potential future sales (6/15) |
|
Notes: # The information in the chart does not cover agreements between biotech companies or agricultural agreements. * Private companies are indicated with an asterisk.Unless otherwise noted, stock symbols listed are on the Nasdaq market. BE = Berlin Stock Exchange. | |||
